EMA Authorised: Zeffix (lamivudine) — GlaxoSmithKline Trading Services Limited

View source ↗

Summary

Zeffix (lamivudine) has been authorised by EMA for chronic hepatitis B.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Hepatitis B

Drugs mentioned

• Zeffix (lamivudine)

Snippet

Status: Authorised. Therapeutic area: Hepatitis B, Chronic. MAH: GlaxoSmithKline Trading Services Limited. Decision date: 22/07/2026